Rapid sugar sensing from gut to brain
从肠道到大脑的快速糖传感
基本信息
- 批准号:10676399
- 负责人:
- 金额:$ 5.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdultAgonistAmericanAntidiabetic DrugsBariatricsBindingBrainCOVID-19Cardiovascular DiseasesCellsChronic DiseaseClustered Regularly Interspaced Short Palindromic RepeatsCoculture TechniquesConsumptionDataDesire for foodDiabetes MellitusDietDoctor of MedicineDoctor of PhilosophyElectrophysiology (science)Energy MetabolismEpithelial CellsFamilyFoodGlucose TransporterGlutamatesGoalsHealthHospitalizationHumanIn VitroIntakeInterventionIntestinesKnock-outLeadershipLifeLigandsMeasuresMediatingMembrane ProteinsMentorsMentorshipMetabolismMusNational Institute of Diabetes and Digestive and Kidney DiseasesNeurobiologyNeuronsNitrogenObesityOrganoidsOxygenPerfusionPharmacologic SubstancePhysiciansPositioning AttributeRecommendationRoleScientistSensorySignal TransductionSodiumStructureTestingTherapeuticTimeTrainingTranscriptVagus nerve structureabsorptioncareercomorbiditydetection of nutrientglucose transporthormonal signalsin vivoinhibitorintestinal epitheliummind controlneurogeneticsnovelpharmacologicreceptorresponsesensorskillssugar
项目摘要
PROJECT SUMMARY/ABSTRACT
The average American adult consumes over 40 pounds of sugar per year. While sugar intake is necessary for
energy metabolism and survival, this overconsumption has led to rampant obesity and diabetes. Therefore, it is
critical to determine the gut-brain circuit that drives sugar overconsumption. Recently, specialized sensory cells
in the intestinal epithelium, known as neuropod cells, were found to sense intestinal sugars and drive sugar
appetite. Neuropod cells sense sugars using sodium-glucose transporters (SGLTs). Most studies on intestinal
sugar sensing have focused on glucose transport ability itself, but little is known about sensing in the absence
of transport. Here, we will use an anti-diabetic molecule specific to human SGLTs to probe whether it is
glucose transport or sensing that is necessary to activate the neuropod cell sugar sensing circuit. My
hypothesis is that sugar sensing, in the absence of transport, will activate neuropod cells, causing glutamate
release and vagus nerve activity. Therefore, I am pursuing the following aims: 1) to determine whether specific
SGLT activation leads to neuropod cell glutamate release and 2) to determine whether an anti-diabetic
molecule leads to rapid, neuropod cell dependent vagal activity. My approach includes neurogenetic
manipulations of intestinal organoids and in vitro and in vivo electrophysiology. These studies may uncover a
pharmacological target for modulating rapid gut-brain control of food choice without perturbing life-sustaining
sugar absorption. My co-sponsors, Drs. Diego Bohórquez, Ph.D. and David D’Alessio, M.D., are experts in
neuropod cell nutrient sensing and hormone signaling in obesity, respectively. Consistent with their long-
established track record of mentorship, the proposed studies and training plan will provide me with the rigorous
scientific training and leadership skills necessary for a career as a physician-scientist based on gut-brain circuit
manipulation as a bariatric intervention.
项目总结/摘要
美国成年人平均每年消耗超过40磅的糖。虽然糖的摄入是必要的,
能量代谢和生存,这种过度消费导致了猖獗的肥胖和糖尿病。因此有
这对确定导致糖摄入过量的肠道-大脑回路至关重要。最近,专门的感觉细胞
在肠上皮中,被称为神经足细胞,被发现可以感知肠道糖并驱动糖
胃口神经足细胞使用钠-葡萄糖转运蛋白(SGLT)感知糖。大多数关于肠道的研究
糖传感主要集中在葡萄糖转运能力本身,但对缺乏葡萄糖转运能力的传感知之甚少
交通工具。在这里,我们将使用一种对人SGLT特异的抗糖尿病分子来探测它是否是
葡萄糖转运或感测是激活神经足细胞糖感测电路所必需的。我
一种假设是,在缺乏转运的情况下,糖的感知将激活神经足细胞,产生谷氨酸盐。
释放和迷走神经活动。因此,我追求以下目标:1)确定是否具体
SGLT激活导致神经足细胞谷氨酸释放和2)确定抗糖尿病药物是否
分子导致快速的神经足细胞依赖性迷走神经活动。我的方法包括神经遗传学
肠类器官的操作以及体外和体内电生理学。这些研究可能会揭示一个
用于调节食物选择的快速肠-脑控制而不干扰维持生命的药理学靶点
糖的吸收我的共同赞助人,迭戈·博霍尔奎兹博士和医学博士大卫·达莱西奥是专家在
神经足细胞营养传感和激素信号在肥胖症。与他们长期的-
已建立的导师跟踪记录,拟议的学习和培训计划将为我提供严格的
科学训练和领导技能,作为一个基于肠道-大脑回路的医生-科学家的职业生涯所必需的
操纵作为减肥干预。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Emily Jean Alway其他文献
Emily Jean Alway的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 5.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 5.27万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 5.27万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 5.27万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 5.27万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 5.27万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 5.27万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 5.27万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 5.27万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 5.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




